News

Interview with Gyanu Lamicchane

Dr. Gyanu Lamichhane

Dr. Gyanu Lamichhane is Assistant Professor, Division of Infectious Diseases at the Johns Hopkins University Center for Tuberculosis Research Labs. This interview was conducted at JHU on November 13, 2009. The following bio is excerpted from this bio sketch (.pdf – 80kb), which includes a list of publications.

My primary interest lies in understanding exactly how M. tuberculosis bacilli grows so that we can develop ways to stop its growth and treat its infection which kills ~9 million people worldwide. I have been pursuing this topic for the last 10 years and identified many genes, proteins and molecules that are required for its survival and growth. Yet more work lies ahead in determining the molecular mechanism for survival and growth of this bacilli. At the present my efforts are focused on understanding the details of peptidoglycan modification of M. tuberculosis so that we can target this vital component of the cell wall. With a formal education/training in Chemistry and Molecular & Cellular Biology I intend to use these expertise to understand the molecular mechanism of bacterial survival/growth and translate it to develop new drugs and therapies against this deadly infection.

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...